Pfizer and BioNTech to seek regulatory authorisation for Covid-19 booster dose
Pfizer and BioNTech believe that a third dose may be needed within six to 12 months after the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jul 21
Pfizer and BioNTech believe that a third dose may be needed within six to 12 months after the…
08 Jul 21
Vyxeos belongs to the antineoplastics class of medicines, developed using the company’s CombiPlex technology platform
07 Jul 21
The announcement follows competition clearances in the US, Japan and other countries, pending regulatory approval in the UK
06 Jul 21
Lumevoq is authorised to treat patients with vision loss due to LHON caused by a mutation in the…
05 Jul 21
GSK and Alector will develop AL001 and AL101 for the treatment of dementia, sclerosis, Parkinson’s disease and Alzheimer’s…
05 Jul 21
The data included new analysis from blood samples obtained from a subset of participants in the Phase 3…
01 Jul 21
Rylaze is indicated for ALL/LBL in paediatric and adult patients, who have developed hypersensitivity to E. coli-derived asparaginase
30 Jun 21
The investment will expand FDB’s capacity for recombinant vaccines and advanced gene therapies in the US and the…
30 Jun 21
Moderna’s Covid-19 vaccine is authorised in more than 50 countries and received Emergency Use Listing (EUL) from the…
29 Jun 21
The approval is based on results from Phase 3 SAkuraStar and SAkuraSky clinical trials of Enspryng in people…